Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study

OBJECTIVE: PARADIGMS demonstrated superior efficacy and comparable safety of fingolimod versus interferon β-1a (IFN β-1a) in paediatric-onset multiple sclerosis (PoMS). This study aimed to report all predefined MRI outcomes from this study. METHODS: Patients with multiple sclerosis (MS) (aged 10–<...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Douglas L, Banwell, Brenda, Bar-Or, Amit, Ghezzi, Angelo, Greenberg, Benjamin M, Waubant, Emmanuelle, Giovannoni, Gavin, Wolinsky, Jerry S, Gärtner, Jutta, Rostásy, Kevin, Krupp, Lauren, Tardieu, Marc, Brück, Wolfgang, Stites, Tracy E, Pearce, Gregory L, Häring, Dieter A, Merschhemke, Martin, Chitnis, Tanuja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231437/
https://www.ncbi.nlm.nih.gov/pubmed/32132224
http://dx.doi.org/10.1136/jnnp-2019-322138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231437/
https://www.ncbi.nlm.nih.gov/pubmed/32132224
http://dx.doi.org/10.1136/jnnp-2019-322138

Ejemplares similares